Key Highlights

  • Capricor Therapeutics (NASDAQ:CAPR) traded near USD 6.63 early on Wednesday, October 21, 2026, far below a 52-week high of about USD 40.37, a month before the Sunday, November 22, 2026 FDA target action date for deramiocel.
  • On Monday, October 5, 2026 the company presented HOPE-3 open-label extension data in which patients switched from placebo showed a 76% reduction in the rate of upper-limb decline in their second year.
  • Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, holds Rare Pediatric Disease designation, which may qualify the company for a Priority Review Voucher, a transferable regulatory asset, upon approval.
  • The 48.91% rise in basic earnings per share in market data is computed on a negative base for a company without approved products, so it reflects a narrowing loss rather than commercial improvement.

A Regulatory Date Approaches

Capricor Therapeutics (NASDAQ:CAPR) develops deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, an inherited disease that progressively destroys muscle in boys. The company submitted a major amendment to its Biologics License Application, the filing that seeks FDA approval, including the open-label extension data, and the FDA target action date is Sunday, November 22, 2026. On Monday, October 5, 2026 it presented HOPE-3 extension data at the World Muscle Society Congress. The shares closed at USD 7.83 on Friday, October 9, 2026 and traded near USD 6.63 early on Wednesday, October 21, giving a market value of about USD 384 million. The company had not issued a release accounting for the decline as of October 21. One-year HOPE-3 results appeared in a peer-reviewed medical journal in July 2026.

How the Extension Data Fit the Approval Case

In the extension, patients first given placebo declined by 2.05 points on the PUL 2.0 upper-limb scale in year one, then by 0.49 points after switching to deramiocel, a 76% reduction in the rate of decline. Patients treated from the start declined by 0.95 and then 0.89 points. The company states that no statistical alpha, the error budget for formal testing, was allocated to these analyses and that natural history comparisons are descriptive. For Capricor Therapeutics (NASDAQ:CAPR), the decision therefore rests on how the FDA weighs controlled and open-label evidence together. The 48.91% earnings improvement is a narrowing loss on a negative base, so valuation depends on the probability of approval, a possible Priority Review Voucher and launch economics with its distribution partner.

Risks and What to Watch

The main risk for Capricor Therapeutics (NASDAQ:CAPR) is a negative or delayed FDA decision, which would remove the core valuation support for a company without approved products. A second risk is the litigation with Nippon Shinyaku and NS Pharma over the existing distribution agreement, which bears on who commercialises deramiocel in the US and on what economics. A third is funding: a company without product revenue faces higher capital costs with the 10-year Treasury yield at 5.12%, and a launch would require spending. Investors should watch FDA communications ahead of the Sunday, November 22, 2026 target date, third-quarter results and cash runway, litigation filings and the Federal Reserve decision on Wednesday, October 28, 2026. Regulatory outcomes cannot be known in advance.

Where Things Stand

The answer is that Capricor Therapeutics (NASDAQ:CAPR) faces a binary regulatory test, with extension data showing a 76% slower decline after switching but without formal statistical weight. The share price near USD 6.63, far below its 52-week high, shows that the market assigns meaningful risk to the outcome. The next catalysts are the November 22 target action date, any FDA labelling discussions and third-quarter results. Regulatory dates are targets, not guarantees, and this is not investment advice.